Navigation Links
PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
Date:7/27/2009

tt R. Plotkin, M.D., Ph.D., director of the Neurofibromatosis Clinic at the Pappas Center for Neuro-Oncology in the Massachusetts General Hospital Cancer Center. "If shown to be efficacious, we believe that its oral administration and generally well-tolerated profile could make PTC299 an especially appealing treatment approach for NF2 patients with growing vestibular schwannomas."

The new PTC299 clinical study is an open-label Phase 2 trial that will evaluate the efficacy, safety, and pharmacodynamics of PTC299 in up to 25 patients with NF2 for up to 48 weeks. The primary objective of the study is to assess how PTC299 affects tumor volume and changes in hearing and word recognition among patients with NF2. The trial will also assess the effects of PTC299 on tumor blood flow and VEGF-related proteins. The study will be conducted at the Massachusetts General Hospital in Boston, Massachusetts.

"We are excited to rapidly advance the clinical development of PTC299 in NF2," said Langdon Miller, M.D., Chief Medical Officer of PTC Therapeutics. "We are hopeful that the novel mechanism of PTC299 will address unmet medical need for patients with NF2, building upon ongoing evaluations of the drug in patients with metastatic breast cancer, Kaposi's sarcoma, and other solid tumors."

In previous Phase 1 clinical studies, PTC299 was generally well tolerated by healthy volunteers who received single or multiple doses, with no serious, dose-limiting or definitively drug-related adverse events reported. All clinical adverse events observed were mild or moderate in severity, did not require intervention, and were not clearly related to PTC299. In addition, adverse events such as bleeding, hypertension and proteinuria were not observed.

The Phase 2 clinical trial of PTC299 is supported by a grant from the U.S. Department of Defense Neurofibromatosis Research Program.

About PTC299
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
2. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
3. Cell Therapeutics, Inc. Announces Exercise of Overallotment
4. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
5. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
7. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
8. Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens
9. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
10. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
11. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... In response to its clients’ ... sales, training and consumer engagement challenges, digital ... applications to turn their clients’ visions into reality. ... mobile app creations, are now featured on its ... with Toyota, StudioPMG created a robust cross-platform mobile ...
(Date:10/1/2014)... October 01, 2014 TeselaGen Biotechnology ... Science Foundation to expand their bioCAD/CAM software suite, which ... modify DNA. The Small Business Innovation Research Phase II ... technology under exclusive license from the Lawrence Berkeley National ... Institute , an LBNL laboratory that develops alternative fuel ...
(Date:9/30/2014)... is available in German . ... several quantum dots in a semiconductor layer. Quantum dots are ... atomic processes. If a short laser pulse is fired at ... quantum dot experiences a change in the electromagnetic field around ... emission of light by the dot. As soon as the ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... Review - 2014 Summary Global Markets ... Review - 2014, provides an overview of the ... focus. This report provides comprehensive information on ... Biotechnology, LLC,s, complete with comparative analysis at various ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3
... Pa., Oct. 5 Genaera,Corporation (Nasdaq: GENR ... at two upcoming conferences, Biotech 2007 in Philadelphia ... San Francisco on October,9-11, 2007. Henry R. ... of Genaera, is scheduled to participate in a ...
... BASINGSTOKE, England and CAMBRIDGE, Massachusetts, October 4, Shire ... that Japan,s Ministry of Health, Labour and Welfare ... the treatment of,Hunter syndrome, for sale and marketing ... ELAPRASE is now approved for marketing and commercial,distribution ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) has entered into a ... to certain terms and conditions of,the agreement, Horizon will ... its option, Pharmasset may receive a second loan of ... of $10 million by November 30, 2008,provided conditions precedent ...
Cached Biology Technology:Genaera to Present at Biotech 2007 and BIO InvestorForum 2Genaera to Present at Biotech 2007 and BIO InvestorForum 3Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome 2Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome 3Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome 4Pharmasset Accesses up to $30 Million of Working Capital 2Pharmasset Accesses up to $30 Million of Working Capital 3
(Date:10/1/2014)... , Finnland, October 1, 2014 /PRNewswire/ ... Durchbruch im Bereich der Biowissenschaften   ... ein Kommen und Gehen zahlreicher Detektionstechnologien. Einige ... zum goldenen Standard. Die Photonen-Upconversion ist eine ... letzten Jahren mit Begeisterung aufgenommen wurde. Jetzt ...
(Date:9/30/2014)... San Diego, have completed the first comprehensive numerical simulation ... the pixels in an image as data points for ... The researchers, led by J.S. Chen, the William Prager ... Engineering at UC San Diego, presented their findings on ... in Pittsburgh this month. Chen also gave a keynote ...
(Date:9/30/2014)... Calif. The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama,s BRAIN (Brain Research ... research effort to revolutionize our understanding of the ...
Breaking Biology News(10 mins):Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... living in densely populated urban areas have a profound impact ... health and fitness of native wildlife. For the first time, ... urbanization and the prevalence and severity of two distinct parasites ... today,s issue of the journal PLOS ONE . ...
... made the world,s temperature records available via Google Earth. ... temperature dataset is one of the most widely used records ... allows users to scroll around the world, zoom in on ... data more easily than ever before. Users can drill ...
... Biological Studies will join Stanford University in leading a ... through a $40 million award by California,s stem cell ... center will bring together experts and investigators from seven ... of genomics the study of the complete genetic ...
Cached Biology News:Presence of humans and urban landscapes increase illness in songbirds, researchers find 2Presence of humans and urban landscapes increase illness in songbirds, researchers find 3World temperature records available via Google Earth 2Salk Institute and Stanford University to lead new $40 million stem cell genomics center 2Salk Institute and Stanford University to lead new $40 million stem cell genomics center 3
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Moue Serum 8-12 Weeks Old...
... Serum • Mouse serum is collected off the clot ... weeks of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
Biology Products: